Shifting GLP-1 Receptor Agonists from Proteins to Small Molecules

In Episode 2 of our GLP-1 Peer Exchange™, experts Judith Hey-Hadavi, vice president at Worldwide Clinical Trials, and clinical pharmacist Nicole Snow from Olympia Pharmaceuticals, discuss the evolution of GLP-1 receptor agonists from protein-based therapies to small-molecule options. They explore the patient-driven shift toward oral therapies, the challenges of bioavailability and tolerability, and strategies for clinicians to optimize treatment, including dose titration, lifestyle integration, and side effect management. The conversation highlights the balance between efficacy, safety, and patient adherence in this rapidly growing therapeutic class.